NDASUBCUTANEOUSSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
LASIX ONYU (furosemide) by Innovation Pharmaceuticals is 12. First approved in 2025.
Drug data last refreshed 16h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX ONYU is a subcutaneous furosemide solution, a loop diuretic that inhibits sodium and chloride reabsorption in the renal tubules to treat fluid overload in heart failure patients. The subcutaneous formulation offers an alternative delivery route to intravenous administration with equivalent diuretic efficacy and an 8+ hour duration of effect. It is indicated for patients with NYHA Class II and III heart failure requiring diuretic therapy.
Launch15.3 years to LOE
Early-stage launch product with no direct competitors in subcutaneous furosemide presents opportunity to build a new delivery category and establish market position, likely requiring lean but highly focused commercial teams.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on LASIX ONYU at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.